One of the other variables right now that is being talked about quite a bit as we approach 2026 is the idea that 2026 will be the year halfway almost halfway through it where we get a new Fed chair, new leadership in that position. What exactly does that have significance towards with regard to not just the rate trajectory but the overall macro backdrop that the Fed's going to have to navigate in those two halves of the year. So here here's how I think about the new Fed chair.At the margin a dovish Fed chai ...

some big retail moves from the investment committee. We're going to start with Bin Talkington. Bin, you just bought Nike and on holding.So, let's start with the Nike trade and why. >> Yeah. So, if you've heard me before, I really don't buy retail names.The investors so finicky. I've listened to the Nike call the last two quarters. I think Elliot Hill, who stepped up as the new CEO, is on track to turning the company around.Obviously, the stock got hammered after they actually had very good earnings, but the ...

We recently published 10 Stocks on Jim Cramer’s Radar.  NIKE, Inc. (NYSE:NKE) is one of the stocks on Jim Cramer's radar. NIKE, Inc. (NYSE:NKE) is a stock that Jim Cramer frequently discusses. The firm reported its second fiscal quarter earnings on December 18th. The results saw NIKE, Inc. (NYSE:NKE)’s $12.43 billion in revenue and $0.53 in earnings beat analyst estimates of $12.22 billion and $0.38. However, media reports suggested that a 17% drop in Chinese revenue contributed to a post-earnings share p ...

is joining us now, Scott Lindiccom, vice president of general economics at the KO Institute. Scott, thanks for joining us this morning. >> Thanks for having me.>> So, I'm not going to deal with what President Trump said. I I But there is a general view, Scott, that tariffs have not been as bad as expected either in inflation or in growth terms. What's your response to that.>> Yeah, I think there's two things. Uh first the there has been some surprises related to the tariffs. Um mainly related to the lack of ...

消费者情绪与通胀预期 - 12月消费者信心指数从密歇根大学初步估计的53.3下修至52.9 但仍高于11月的51.0 [4] - 消费者对未来一年的通胀预期连续第四个月下降至4.2% 为11个月来最低水平 但仍高于1月份的3.3% [5] - 消费者信心的改善集中在低收入群体 而高收入消费者的情绪保持稳定 [5] 科技巨头资本支出与AI竞赛 - 大型科技公司正投资数十亿美元用于AI基础设施 以加速AI领域的领先地位 [9] - Meta Platforms预计2025年资本支出（包括融资租赁本金付款）在700亿至720亿美元之间 高于此前660亿至720亿美元的展望 [10] - Meta表示明年将“积极支出” 并警告2026年资本支出将“显著增加” 总支出将以“明显更快的百分比速度”增长 [11] - Alphabet将2025年资本支出预期上调至910亿至930亿美元 高于此前850亿美元的估计 [12] - Alphabet高级副总裁兼CFO表示 投资激增源于云客户的需求和公司整体的增长机会 [12] - 亚马逊第三季度现金资本支出为342亿美元 今年迄今已支出899亿美元 公司将继续进行重大投资 特别是在AI领域 [13] 2026年标普500指数展望 - 预测标普500指数将在2026年再上涨10-15% [14] - 看涨观点基于科技股背后的顺风因素 包括其巨额支出 以及构成标普指数一半权重的十大公司大多不受关税影响 [14] - 这些公司即使在进入AI这种预计利润率很低的业务时 似乎也在持续扩大其利润率 [14]

消费者情绪与通胀预期 - 12月消费者信心指数从密歇根大学初步估计的53.3下修至52.9 但仍高于11月的51.0 [4] - 消费者情绪改善主要集中在低收入群体 而高收入消费者情绪保持稳定 [5] - 未来一年通胀预期连续第四个月下降至4.2% 为11个月来最低水平 但仍高于1月份的3.3% [5] - 11月消费者价格指数同比上涨2.7% 但存在显著地区差异 例如南加州同比通胀为4.5% 而达拉斯仅为1.1% [4] 关税与贸易前景 - 2025年4月2日的关税税率已不再适用 市场对最初宣布的反应可能过于悲观 [7] - 目前处于为期一年的贸易休战期 2026年大部分时间将用于谈判最终结果 其走向存在不确定性 [8] 科技巨头AI资本支出竞赛 - 大型科技公司正投资数十亿美元用于AI基础设施 以加速在AI领域的领先地位 [9] - Meta Platforms将2025年资本支出预期上调至700亿至720亿美元 此前预期为660亿至720亿美元 [10] - Meta警告称2026年资本支出将“显著增加” 总费用将以“明显更快的百分比速度”增长 [11] - Alphabet将2025年资本支出预期上调至910亿至930亿美元 此前估计为850亿美元 [12] - Alphabet表示由于云客户的需求和公司各领域的增长机会 将继续积极投资 [12] - 亚马逊第三季度现金资本支出为342亿美元 今年迄今已支出899亿美元 并指出将继续进行重大投资 特别是在AI领域 [13] 2026年标普500指数展望 - 预测标普500指数将在2026年再上涨10%至15% [14] - 看涨观点基于科技股背后的顺风因素 包括其巨额支出 以及主要成分股公司对关税的免疫性 [14] - 主要科技公司似乎即使在进入AI这种预计利润率较低的业务时 也能持续扩大其利润率 [14]

Jim Cramer, the host of Mad Money, said on Monday that he wanted to revisit the major macro questions he asked at the start of 2025 and see how events actually played out. “Okay, I came up with four big macro questions… First question, does the yield on the 10 Year Treasury go to 4% or 5% first, or neither?… This is one where we got a definitive answer because the 10 Year went to 4% first… What happened in 2025? Specifically, the 10 Year broke below 4% briefly in that post-Liberation Day washout last spring ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

安进公司与政府达成药品定价协议 - 安进公司与特朗普政府签署了一项具有里程碑意义的协议，以降低其药品在美国的价格[1] - 该协议旨在解决困扰大型制药公司的两大核心问题：药品定价和关税[2] - 协议要求公司将已上市药品的价格与其他发达国家市场看齐，并通过直接面向消费者渠道和TrumpRx.gov政府平台为美国公民提供大幅折扣[2] 安进公司具体降价与投资计划 - 公司于10月推出了名为AmgenNow的直接面向消费者计划，率先将其重磅降胆固醇药物Repatha的价格定为每月239美元，较美国标价折扣近60%[3] - 公司将AmgenNow计划扩展至偏头痛药物Aimovig和修美乐生物类似药Amjevita，价格均为每月299美元，较各自美国标价分别折扣60%和80%[3] - 作为降低药价的交换，公司预计将获得为期三年的药品成分进口关税豁免，条件是扩大国内产能[4] - 安进公司此前已宣布计划今年额外投资25亿美元，以加强其在美国的生产和研究能力[4] - 具体投资包括在加利福尼亚州投资6亿美元建设科学与创新中心，在俄亥俄州投资9亿美元扩大生产，以及在北卡罗来纳州投资10亿美元建设设施[4] 行业广泛参与与投资者情绪 - 安进并非孤例，另有八家大型制药公司（百时美施贵宝、葛兰素史克、默克、基因泰克、吉利德科学、诺华、赛诺菲和勃林格殷格翰）也与政府宣布了类似协议[5] - 此前，辉瑞、阿斯利康、礼来、诺和诺德和默克集团已在过去几个月与政府签署了类似协议[5] - 截至目前，特朗普政府已与7月份被点名的17家大型制药公司中的14家达成了协议[7] - 剩余三家（艾伯维、强生和再生元）尚未签署协议，仍在与政府积极讨论[7] - 部分制药商还同意向政府储备库捐赠关键产品的活性药物成分，以保障紧急情况下的供应链韧性[6] - 例如，百时美施贵宝将捐赠约6.5吨用于抗凝血药艾乐妥的API阿哌沙班，默克计划捐赠约3.5吨抗菌药厄他培南，葛兰素史克将供应近99公斤用于哮喘吸入器的沙丁胺醇API[6] - 此轮协议公告改善了投资者对整个制药行业的展望，因其标志着政府与大型制药公司之间更合作的态度[7] 安进公司股价表现与估值 - 安进公司股价年内表现优于行业整体水平[8] - 从估值角度看，公司股票交易价格较行业有折价，基于市盈率，其远期市盈率为15.34倍，而行业平均为17.48倍[11] - 公司当前股价高于其五年平均市盈率13.75倍[11] - 过去60天内，市场对安进公司2025年和2026年的每股收益预期有所上调[12]

Let's bring in Bill Simon, former CEO of Walmart US and Michael Baker, DA Davidson, retail analyst. Um, gentlemen, good to see you. Bill, I'll start off with you.Um, and and obviously I I know that you've been in favor of Walmart obviously for a long time, but I mean, at this point, uh, you know, it's it's hands down the favorite, I think, across retail analysts, amongst investors as well. It it has a premium valuation. At what point do you say everything's been factored in.It is getting too expensive relat ...